Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > DDC


Brief Information

Name:Aromatic-L-amino-acid decarboxylase
Target Synonym:EC:,EC 4.1.1,DDC,AADC,Dopa Decarboxylase (Aromatic L-Amino Acid Decarboxylase),Aromatic-L-Amino-Acid Decarboxylase,Aromatic L-Amino Acid Decarboxylase,EC,DOPA decarboxylase
Number of Launched Drugs:8
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
DDC-H55H6 Human Human DDC / Dopa Decarboxilase Protein, His Tag (MALS verified)
ACRO Quality

Synonym Name

Aromatic-L-amino-acid decarboxylase,Dopa decarboxilase


Dopa decarboxilase (DDC), also known as aromatic amino acid decarboxylase, is a group II decarboxylase. The enzyme catalyzes the decarboxylation of aromatic L-amino acids to produce the corresponding amines. DDC produces the neurotransmitters dopamine and serotonin from L-Dopa and L-5-hydroxytryptophan, respectively.  DDC inhibitors is in clinical use to treat Parkinson's disease(PD), usually co-administrated with L-DOPA. DDC would block peripheral conversion to dopamine and allow a greater percentage of L-DOPA to reach the brain, causing an increase in brain dopamine levels, and reducing the side effects of dopamine-rich blood.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Levodopa/Benserazide Hydrochloride Approved F. Hoffmann-La Roche Ltd Madopar Switzerland Parkinson Disease F. Hoffmann-La Roche Ltd 1973-06-27 Parkinson Disease Details
Eladocagene exuparvovec PTC-AADC Approved National Taiwan University, Ptc Therapeutics Inc Upstaza EU Amino Acid Metabolism, Inborn Errors Ptc Therapeutics International Ltd 2022-07-18 Aromatic amino acid decarboxylase deficiency; Amino Acid Metabolism, Inborn Errors Details
Levodopa/Carbidopa IPX-066; ABT-SLV-187; ND-0680; ND-0612L; AP-CD/LD; ND-0612; IPX-054; ABT-SLV187; IPX-203; CP-012; AP-09004; DM-1992; AP-CDLD; TPI-926; ND-0612H; PW-4153; LCIG; JM-012; SOL-707; INP-107(POD™ carbidopa/levodopa) Approved Merck Sharp & Dohme Corp Numient, Menesit, Duodopa, Vadova, Sinemet, Rytary, Isicom, Duopa, Flexilev, Nacom (imciromab), Nacom retard, Parcopa, DopaFuse, Patrome United States Parkinson Disease; Parkinson Disease, Secondary; Parkinson Disease, Postencephalitic Merck & Co Inc 1975-05-02 Albinism, Oculocutaneous; Diabetes Mellitus; Amyotrophic Lateral Sclerosis; Diabetic Retinopathy; Albinism; Cocaine-Related Disorders; Amblyopia; Depressive Disorder, Treatment-Resistant; Cognitive Dysfunction; Motor Neuron Disease; Aphasia, Broca; Parkinson Disease; Stroke; Parkinson Disease, Postencephalitic; Depression; Parkinson Disease, Secondary; Gait Apraxia Details
Benserazide Hydrochloride Ro-4-4602 Approved Mainland China Parkinson Disease; Dyskinesias Shanghai Yishengyuan Pharmaceutical Co Ltd 1995-01-01 beta-Thalassemia; Dyskinesias; Parkinson Disease; Anemia, Sickle Cell Details
Foslevodopa/Foscarbidopa ABBV-951 Approved Abbvie Inc VYALEV, Vyalev, Duodopa, Produodopa Romania, Belgium, Cyprus Parkinson Disease Abbvie Deutschland Gmbh & Co Kg, Abbvie Sa, Abbvie Inc Parkinson Disease Details
Carbidopa/Entacapone/Levodopa ELC-200; ODM-101 Approved Orion Pharma Stalevo, LECIGon, Trigel, LECIGel, 达灵复 United States Parkinson Disease Orion Pharma A/S 2003-06-11 Parkinson Disease Details
Carbidopa MK-486 Approved Lodosyn United States Parkinson Disease Aton 1977-04-25 Postural Orthostatic Tachycardia Syndrome; Parkinson Disease; Orthostatic Intolerance Details
Carbidopa/Melevodopa V-1512; GT-1512; CHF-1512; CNP-1512 Approved Chiesi Farmaceutici SPA Sirio Italy Parkinson Disease null 2003-01-01 Parkinson Disease Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Buspirone/Carbidopa/Levodopa Phase 2 Clinical Universite Laval Spinal Cord Injuries; Multiple Sclerosis Details
Levodopa/Carbidopa controlled release tablets-night(WD Pharmaceutical) WD-1905 Phase 2 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details
Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical) WD-1603 Phase 2 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details
Levodopa/Carbidopa (Hengrui Medicine) HRG-2010 Phase 2 Clinical Jiangsu Hengrui Medicine Co Ltd Parkinson Disease Details
Ezaladcigene resoparvovec VY-AADC; VY-AADC01; GZ-404477; AV-201; VY-AADC02 Phase 1 Clinical University Of California, Voyager Therapeutics Inc Aromatic amino acid decarboxylase deficiency; Parkinson Disease Details
Carbidopa/oxytriptan EVX-101 Phase 1 Clinical Evecxia Therapeutics Inc Depression Details
VGN-R09 VGN-R09b; VGN-R09 Phase 1 Clinical Shanghai Vitalgen BioPharma Co Ltd Aromatic amino acid decarboxylase deficiency Details
Levodopa/Carbidopa granule(WD Pharmaceutical) WD-2010 Phase 1 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details
Levodopa/Carbidopa(WD Pharmaceutical) WD-1804 Phase 1 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message